ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Bugworks Research Announces the First in Human Phase 1 Study of BWC0977 for the Treatment of Critical Bacterial Infections
November 08, 2021Bugworks research today announced that the first human dose was administered in a Phase 1 clinical trial evaluating BWC0977: a next generation broad-spectrum, novel bacterial topoisomerase inhibitor (NBTI)... -
GARDP and Bugworks sign MoU to develop antibiotics for serious bacterial infections
August 31, 2020The collaboration includes working together for the preparation of regulatory strategies, in particular for clinical development programmes and post-approval studies. -
Bugworks Research raises $9M in series A funding
August 20, 2018Bugworks' novel bacterial topoisomerase inhibitor (NBTI) is highly effective against a very broad spectrum of multi-drug resistant bacterial pathogens
Pharma Sources Insight January 2025
